{"name":"Noven Pharmaceuticals, Inc.","slug":"noven-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Diclofenac Sodium Active Topical Patch 2","genericName":"Diclofenac Sodium Active Topical Patch 2","slug":"diclofenac-sodium-active-topical-patch-2","indication":"Musculoskeletal pain","status":"phase_2"},{"name":"Diclofenac sodium active topical patch","genericName":"Diclofenac sodium active topical patch","slug":"diclofenac-sodium-active-topical-patch","indication":"Localized pain and inflammation associated with minor strains, sprains, and contusions","status":"phase_3"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Diclofenac Sodium Active Topical Patch 1","genericName":"Diclofenac Sodium Active Topical Patch 1","slug":"diclofenac-sodium-active-topical-patch-1","indication":"Pain relief","status":"phase_2"}]}],"pipeline":[{"name":"Diclofenac Sodium Active Topical Patch 1","genericName":"Diclofenac Sodium Active Topical Patch 1","slug":"diclofenac-sodium-active-topical-patch-1","phase":"phase_2","mechanism":"Diclofenac Sodium is a non-selective COX-2 inhibitor.","indications":["Pain relief","Inflammation"],"catalyst":""},{"name":"Diclofenac Sodium Active Topical Patch 2","genericName":"Diclofenac Sodium Active Topical Patch 2","slug":"diclofenac-sodium-active-topical-patch-2","phase":"phase_2","mechanism":"Diclofenac Sodium is a non-selective COX-2 inhibitor.","indications":["Musculoskeletal pain","Arthritis"],"catalyst":""},{"name":"Diclofenac sodium active topical patch","genericName":"Diclofenac sodium active topical patch","slug":"diclofenac-sodium-active-topical-patch","phase":"phase_3","mechanism":"Diclofenac sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain when applied topically.","indications":["Localized pain and inflammation associated with minor strains, sprains, and contusions","Osteoarthritis pain (localized)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE1kcXN4MEtlUUlUMEF5MklBZUItRHhKbkRDSTZnWDZod2x4eTQ3MWJqbmJJVHdXQUlxRlEtZUUxeXRjVkZaM0ZOWnJsbmJneUtLdzFFTDloSlcydW5JdkNLMXlOV2xRYnA2QWJlX2VmWDJZeGstQmt5TnJKZmFRQQ?oc=5","date":"2026-01-21","type":"pipeline","source":"Market.us","summary":"Transdermal Drug Delivery Systems Market Size | CAGR of 11.8% - Market.us","headline":"Transdermal Drug Delivery Systems Market Size | CAGR of 11.8%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxQU29HeWJraDVkUEVCTjB5SC0tbERSd2NDMDByYllGeU9KcVU5U2djZFpubzhiamNWdHluMGZoLWRCYjA3XzYwYXQ3SWhCN2UyS0tMMFltRU5MMmYzT18wOFpKenV2QmQwclRxd3lCWkliYW9rTXdHdjNPTkVjYnhNcnV3ckppREJlQzFDZ183UUFGMFRVTGNRSktpa2dRUzN2eVRTYk1Vbm9CRXBTUDF0R2YzWXdpb29kV3MyRklnY1ZMN1hZTnpsZmZmMmRzNk1kSjZkZ3BFeFFDMHdm?oc=5","date":"2025-01-14","type":"pipeline","source":"Business Wire","summary":"Noven Debuts Optional Companion App for Patients with ADHD – Mindful Patch – at APSARD 2025 - Business Wire","headline":"Noven Debuts Optional Companion App for Patients with ADHD – Mindful Patch – at APSARD 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQV01IUlZ6dUtTRFJRT1k1SUg1aGt2MGVwcS1ITHh5bUhXUXNBeE1KYkVqWFJjQUt6Q3pScGZsNktIOWF1MmxCMmVMOTRMbU14d3VpZlF1ams2ZzRGWERHVHVkNm9WMWlvWVdsRXl5S3lSaERwb19jcTVxT1YwNFYtTnBzc2NxMk5FMFNDazlfVDltMlZ2Z1V6a3JfVnI4N0U?oc=5","date":"2024-03-26","type":"pipeline","source":"Miami Today","summary":"Japanese drugmaker Noven gets county aid to expand here - Miami Today","headline":"Japanese drugmaker Noven gets county aid to expand here","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxONU41U0dTaHF1WTkxRFExTzNNd2l6QmQtbkFjRm8tRjE3MnNvSFBlYVNzLVp1Z2FTMzdtVXpmMzdHUHc1ZlhES2lQUnVMN1dHVW1pMGg3WDcwem02RnE3RDA3NWpIckYyNDhldGp0a3JZNU5nM2pVZTlkTWsyNDZNb19vcHdJdVdDdUFIMVA5VkM4OHZaZ0tSdHNjTnFqUHhXd09nQlhjQms?oc=5","date":"2024-03-13","type":"pipeline","source":"The Business Journals","summary":"Manufacturing firm seeks Miami-Dade incentives for expansion - The Business Journals","headline":"Manufacturing firm seeks Miami-Dade incentives for expansion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQcTZQUDNJNmdNWlA3RjdjWGtpYkE4MlVXdm9IQldPeFNpa3ZfUEpCbnJ4MldkNDJXWGJhZlZsdGN3UnF4eE5uTnNhNlpKLTctY29OMm1NeHAwa2pqbGEwUk1CY1ZXZkpPSHo5T0w4WG5GYVdyWTNJcUZtb2M2VkZnQjk0d3ZYUXI1MHpSWVNxYXh2ZHRCZ1JpVFZxQ0Q2T2NLcVY2SHZBa2lHSkFhWjRZ?oc=5","date":"2023-08-24","type":"pipeline","source":"The Business Journals","summary":"Pharmaceutical company could expand Miami-Dade County campus - The Business Journals","headline":"Pharmaceutical company could expand Miami-Dade County campus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNbU8xWVdianc1djVkd2dWMTRPempBZ3FCMVU5SDN0T05yS0ZNWHhPbmxiMUtYMVpEZ2F2X2IyZ2Z5Y004Q1VmQmVrTjJzUzZkM1oxTlVwREJHelMyaExPNmk0ZHkzS1lrc2l0eXdkdDZPNDAxNkxPUV9tRHdvQi1nR1Z3dS1yQQ?oc=5","date":"2023-03-17","type":"pipeline","source":"Dermatology Times","summary":"Leon Kircik, MD, FAAD: The Evolving Acne Arsenal - Dermatology Times","headline":"Leon Kircik, MD, FAAD: The Evolving Acne Arsenal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAJBVV95cUxOUHZULTlDRXVnYzJWMTRpeGRhdHdjWkRwejVSX3VPekp4ZWRydXlHOFNMaE5Ham1PdWtmMkx1bnM0TVBkZHg4d2xIMXN2U2g1aVZiNTdqelh6M0RwTXI4M3pocDdTSkRYVEtGbGVtQzNhVHdSVEhKeTBCRVhNTzJPbkRHYXdwMGJXbk1jN2J1MmxXZTdvdG4yb0ZCZG9rQjAxT2FMU0JLcC1hVkZNQTdnRUZ4Wk1UR3Q2RVJKUjFqM2ppc2JwRVlwdW45b1BRanh3WXAxMXRrQ0ljYlE1Xy1rUXR6NzVvajRGV2dWekJhSURiZGd2bWZxODBpRXFuQlFaWW5handZZWM4dXRRakp6YmctaDE3ZThzcmU3Zng2TUtBaElxRGhWbl83R09OWHI4dWY1aUN3dmtrVDBuOFk3aG01aVpFT2ljMU5rNQ?oc=5","date":"2023-01-10","type":"pipeline","source":"PR Newswire","summary":"XELSTRYM™ (dextroamphetamine) transdermal system, CII, to be revealed as available soon at the 2023 American Professional Society of ADHD and Related Disorders (APSARD) Conference - PR Newswire","headline":"XELSTRYM™ (dextroamphetamine) transdermal system, CII, to be revealed as available soon at the 2023 American Professiona","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQclN4eEtwZFNFOUtHUVd6N0xSS2lxaDlhX09ZRGVQbVpqZlk3eHU5YmVZd3cydDNoTnZSRllHZ1dNbzVLX0FhdUZzMURzQ3VGck1yLUtic3N3VWN2YThIbjhBYVhRTVR2c3Q5VEZoQWkyYTNKRHFzVzJVWnpuREN3REtrRDVzQk5GZTV6SExuZDZkV0FZa0VPRy1vY1Izck9YRlZOdVhWaUphYWM5MjN4MlJnSkRyekFtQmQySVRwdE83UFk?oc=5","date":"2022-11-10","type":"pipeline","source":"PR Newswire","summary":"NOVEN TO PARTICIPATE IN ANNUAL INTERNATIONAL CONFERENCE ON ADHD (CHADD) - PR Newswire","headline":"NOVEN TO PARTICIPATE IN ANNUAL INTERNATIONAL CONFERENCE ON ADHD (CHADD)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPTW0zWGJDQndsU0JVaGNkaE8yMHZjUEZnVFZLM0lJX3Nsa0Q3VzdCTnRUMFRMbHRqYzQyRENuSGNKUXpReHVJZXJTWUVEZkdKdTZlU3V1MkVIdEJGYVZSZE1RY0VQZ25PWjhVRGs0b3Rab19WZ0ZTMjVjZlBSSjhkbTNwN2VvcjhXdTVJTnBWX1I?oc=5","date":"2022-03-16","type":"pipeline","source":"Yahoo Finance","summary":"Drugs For Hormonal Replacement Therapy Global Market Report 2022 - Yahoo Finance","headline":"Drugs For Hormonal Replacement Therapy Global Market Report 2022","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPUzZGZ2I2Q3gtaG4tcXpMcXhGcFQ3aTV4eUY4SnBJZXFiMEhJU3FHd0F6ZDNESXU3bGVoU1RuQXJNTDRZemo1ZjI4cGhDSnFTbnhMaFJBMTEtTy1yazZiVGI0czMzYW5haVlDYWc4ZzBjWUtwWnUyRy1HZnE0RnZkUXp6a3pnUVRGbDZGeGR5X3VkNTVWdVgxZmt2QQ?oc=5","date":"2019-10-15","type":"regulatory","source":"BioSpace","summary":"FDA Approves Noven Pharmaceuticals’ Transdermal Patch for Schizophrenia - BioSpace","headline":"FDA Approves Noven Pharmaceuticals’ Transdermal Patch for Schizophrenia","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOdnhvdGhqVS1Dbk5uOE5SemVnMnFUV3V3eXFBUjM3RS05SE9Ncm9zWnk3RmRaX2FKTEZ3Vm9SeDd3U1RfdTd0amhKNzJtNndvU3FmSTdwWGw0RzVMS09uYWdEQWstNkNleXRWbjRFNldHY3lwSlBhVmR5SW1NbWRfRm9rVFg3ZXNMTnJ3eGZRZVBRTkU0LWc?oc=5","date":"2016-12-31","type":"regulatory","source":"Pharmaceutical Online","summary":"FDA approves Vivelle's osteoporosis prevention indication - Pharmaceutical Online","headline":"FDA approves Vivelle's osteoporosis prevention indication","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQWnFjLTBpVWVwM0ZaaktGdmpvZ044Rk1kOFBtay1XVWxKZDcyUUJpX1JmTmhSRFBMV3Voenp3eWpKX3ZwRjhGNXJIT2xVZjJjR0JYdnBrMFVvcGdrVUFKbDc2YUNsaE5XTER3b2dBQ1V3dkg1WE1MTURwRG9FMC1IS2FkdjlMMThDWFJPbGs0Mk4tNnJqNkE4TUxJVV9LZklGRmNJ?oc=5","date":"2013-11-05","type":"pipeline","source":"multivu.com","summary":"Noven Pharmaceuticals, Inc. - multivu.com","headline":"Noven Pharmaceuticals, Inc.","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":2,"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}